Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C19 Genotype and Clopidogrel Therapy: 2013 Update. Issue 3 (22nd May 2013)

• Record Type: Journal Article
• Authors: Scott, S A; Sangkuhl, K; Stein, C M; Hulot, J‐S; Mega, J L; Roden, D M; Klein, T E; Sabatine, M S; Johnson, J A; Shuldiner, A R
• Is Part Of: Clinical pharmacology & therapeutics. Volume 94:Issue 3(2013)
• Page Start: 317
• Page End: 323
• Publication Date: 2013-05-22
• Subjects: Pharmacology -- Periodicals; Therapeutics -- Periodicals; 615.5
• DOI: 10.1038/clpt.2013.105
• Languages: English
• ISSNs: 0009-9236

Abstract

<abstract abstract-type="main"> <title> <x xml:space="preserve">Abstract</x> </title> <p>Cytochrome P450 (CYP)2C19 catalyzes the bioactivation of the antiplatelet prodrug clopidogrel, and <italic>CYP2C19</italic> loss‐of‐function alleles impair formation of active metabolites, resulting in reduced platelet inhibition. In addition, <italic>CYP2C19</italic> loss‐of‐function alleles confer increased risks for serious adverse cardiovascular (CV) events among clopidogrel‐treated patients with acute coronary syndromes (ACSs) undergoing percutaneous coronary intervention (PCI). Guideline updates include emphasis on appropriate indication for <italic>CYP2C19</italic> genotype–directed antiplatelet therapy, refined recommendations for specific <italic>CYP2C19</italic> alleles, and additional evidence from an expanded literature review (updates at <ext-link ext-link-type="uri" xlink:href="http://www.pharmgkb.org" xlink:type="simple" xmlns:xlink="http://www.w3.org/1999/xlink">http://www.pharmgkb.org</ext-link>).</p> <p> <italic>Clinical Pharmacology &amp; Therapeutics</italic> (2013); <bold>94</bold> 3, 317–323. doi:<ext-link ext-link-type="doi" xlink:type="simple" xmlns:xlink="http://www.w3.org/1999/xlink">10.1038/clpt.2013.105</ext-link></p> </abstract>